Analisi delle dimensioni del mercato della diagnostica molecolare Point of Care fino al 2028

  • Report Code : TIPRE00003144
  • Category : Medical Device
  • Status : Published
  • No. of Pages : 208
Buy Now

[Rapporto di ricerca] Si prevede che il mercato della diagnostica molecolare point-of-care raggiungerà 5.381,18 milioni di dollari < /span>entro il 2028 da 2.230,94 milioni di dollari nel 2021; si prevede che crescerà a un CAGR del 13,4% dal 2021 al 2028.

Approfondimenti di mercato e visione degli analisti:

La diagnostica molecolare al punto di cura include dispositivi portatili e test e analisi. kit utilizzati per rilevare e diagnosticare malattie in campioni umani, come tamponi faringei, sangue, siero e feci. La diagnostica molecolare si sta spostando dai laboratori centralizzati ai test molecolari decentralizzati presso i punti di cura, grazie alla sua semplicità, praticità, tempi di consegna rapidi e potenziale di miglioramento dei risultati sui pazienti. Grazie a questi vantaggi, può essere applicato per la diagnosi in aree con poche risorse o remote. La crescente incidenza delle malattie infettive ha notevolmente aumentato la domanda di diagnosi efficaci. La crescente domanda di strumenti diagnostici per controllare ed eliminare le malattie infettive, il rilevamento tempestivo dell’agente causale, consentendo un trattamento efficace e il controllo delle malattie alimenteranno il mercato durante il periodo di previsione. Inoltre, le tecniche moderne stanno consentendo un notevole rinnovamento nel campo della diagnostica molecolare. Si prevede che la dimensione globale del mercato della diagnostica molecolare point-of-care raggiungerà i 5.381,18 milioni di dollari nel 2028 dai 2.230,94 milioni di dollari nel 2021. Si stima che il mercato crescerà con un CAGR del 13,4% dal 2021 al 2028.

Driver di crescita e sfide:

L'aumento dell'incidenza delle malattie infettive

La crescente diffusione delle malattie infettive aumenta il livello e il tasso di test. Lo spostamento dei test diagnostici molecolari per le malattie infettive dai laboratori ai punti di cura può potenzialmente rivoluzionare la velocità e la quantità di test da eseguire. La diagnostica molecolare è un prodotto e un servizio più sensibile che consente il rilevamento di concentrazioni minori di agenti patogeni infettivi, consentendo il rilevamento delle malattie prima di quanto consentito in precedenza. La diagnostica molecolare presso il punto di cura offre il potenziale per ridurre al minimo il tempo necessario per ottenere un risultato utilizzabile e promuovere il rilevamento precoce delle infezioni, misure appropriate di controllo delle infezioni e l’arruolamento in studi clinici terapeutici. La crescente prevalenza dell’influenza A/B, del virus respiratorio sinciziale (RSV) e delle infezioni acquisite in ospedale (HAI) aumenta la domanda di test molecolari presso il punto di cura. I test presso il punto di cura dell’influenza e del virus respiratorio sinciziale (RSV) possono migliorare il trattamento dei pazienti e il controllo delle infezioni. Recentemente, la diagnostica molecolare presso il punto di cura ha svolto un ruolo cruciale nel rilevamento dell’infezione da COVID-19. Per il rilevamento dell’infezione da COVID-19, i test diagnostici basati su RT-PCR richiedono tempo, sono costosi e richiedono attrezzature avanzate e personale specializzato. L’alto costo della diagnosi e la scarsità di kit di test hanno reso difficile monitorare la trasmissione nella comunità. Di conseguenza, erano urgentemente necessari approcci rapidi, convenienti ed efficaci per rilevare l’infezione virale da COVID-19 nelle persone. I dispositivi diagnostici molecolari facili ed efficaci presso il punto di cura consentono test in loco, che aiutano nella prevenzione dell'infezione e nel controllo della sua diffusione. Pertanto, la crescente domanda di kit molecolari rapidi ed efficaci per il punto di cura per rilevare le malattie infettive guida la crescita del mercato.

Approfondimenti strategici

Restrizioni del mercato

Pressioni sui prezzi a causa dei tagli ai rimborsi

Il mercato della diagnostica sanitaria attualmente soffre di una carenza di rimborsi per diversi metodi, cruciali per la diagnosi del paziente. L’assenza di rimborsi ha un impatto negativo sul mercato, con i grandi mercati nelle principali economie che registrano una crescita piatta. I test di diagnostica molecolare presso il punto di cura si trovano ad affrontare problemi simili di rimborsi insufficienti in vari paesi del mondo. Il sistema di rimborso è solitamente ostile ai test diagnostici. Poiché i test diagnostici sono sotto-rimborsati, i prezzi dei test sono troppo bassi, il che alla fine diminuisce la redditività del settore e le dimensioni del mercato. Inoltre, strutture di rimborso inefficienti costituiscono un ostacolo allo sviluppo di test diagnostici migliori. Inoltre, i tagli ai rimborsi potrebbero avere un impatto negativo sulla pratica clinica, poiché deve far fronte sia alla riluttanza a utilizzare la diagnostica sia alla mancanza di test migliorati in futuro. Inoltre, i paesi hanno le proprie strutture e politiche di rimborso quando si tratta di trattamenti specifici. Ad esempio, le autorità negli Stati Uniti e in Germania risarciscono gli ospedali per il costo totale del trattamento di una malattia. Pertanto, se il paziente rimane in ospedale più a lungo del previsto, gli ospedali si fanno carico delle spese. Questo scenario può ostacolare l’uso di strumenti diagnostici se ospedali e centri sanitari ritengono che ulteriori test comporterebbero una perdita di profitto o una perdita finanziaria per paziente. Pertanto, i produttori di apparecchiature originali (OEM) di dispositivi diagnostici molecolari point-of-care devono affrontare numerose sfide burocratiche e tariffarie a causa delle rigide strutture di rimborso. Pertanto, i problemi di rimborso stanno creando pressioni sui prezzi sui produttori di dispositivi di diagnostica molecolare point-of-care, il che costituisce un importante freno per la crescita complessiva del mercato della diagnostica molecolare point-of-care.

Segmentazione e ambito del rapporto:

La "diagnostica molecolare globale al punto di cura" ; è segmentato in base al prodotto e al; servizi, tecnologia, applicazione, utente finale e geografia. Sulla base di prodotti e servizi, il mercato globale della diagnostica molecolare per il punto di cura è segmentato in test e kit, strumenti, servizi e software. Il mercato della diagnostica molecolare point-of-care basato su questa tecnologia è segmentato in PCR, tecnologia di amplificazione isotermica degli acidi nucleici (INAAT) e altre tecnologie. Il mercato della diagnostica molecolare point-of-care basato sull'applicazione è segmentato in malattie infettive, oncologia, ematologia, test prenatali, endocrinologia e altre applicazioni. Il mercato della diagnostica molecolare point of care in base all'utente finale è segmentato in ospedali e cliniche, laboratori diagnostici, istituti accademici e di ricerca e altri.

Il point of care molecolare La diagnostica nei mercati sanitari commerciali in base alla geografia è segmentata in Nord America (Stati Uniti, Canada e Messico), Europa (Germania, Francia, Italia, Regno Unito, Russia e resto d'Europa), Asia Pacifico (Australia, Cina, Giappone, India , Corea del Sud e resto dell'Asia Pacifico), Medio Oriente e altri paesi. Africa (Sudafrica, Arabia Saudita, Emirati Arabi Uniti e resto del Medio Oriente e dell'Africa) e Sud e Africa. America centrale (Brasile, Argentina e resto dell'America meridionale e centrale)

Analisi segmentale:

Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are point-of-care molecular diagnostics?

Point-of-care molecular diagnostics include portable devices, and assays & kits used to detect and diagnose diseases in human samples, such as throat swab, blood, serum, and stool. Molecular diagnostics are shifting from centralized laboratories to decentralized point-of-care molecular testing, due to its simplicity, convenience, rapid turnaround time, and potential to improve patient outcomes.

What are the driving factors for the point-of-care molecular diagnostics market across the globe?

Increasing demand for diagnostic tools to control and eliminate infectious diseases, timely detection of causative agent, allowing effective treatment and disease control will fuel the market during the forecast period.

Who are the developments carrying out by major players in the point-of-care molecular diagnostics market?

Various companies have made organic growth strategies in the point-of-care molecular diagnostics market. Some of the activities undertaken by the company, which have promoted its growth are, launches, enhancements and expansion & relocation activities. Companies such as F. Hoffmann-La Roche Ltd, Danaher amongst others are some of the companies that have been implementing various organic strategies that have helped the growth of the company.

Which region is dominated the Point-of-Care Molecular Diagnostics market?

North America dominates the global point-of-care molecular diagnostics market. Ongoing efforts by major market participants to strengthen their market position is an important factor contributing to the major share. Furthermore, several clinical studies investigating the efficiency and accuracy of novel molecular tests are also expected to contribute towards the market growth over the forecast period. Growing demand for rapid diagnosis and development of newer molecular diagnostic tests for DNA analysis have poised the region as a major market space.

Which region is the fastest growing in the Point-of-Care Molecular Diagnostics market?

Asia Pacific is expected to be the fastest growing region in the point-of-care molecular diagnostics market. The growth of the point-of-care molecular diagnostics market in this region is primarily due to rising incidences of chronic diseases associated with geriatric population, expansion of key market players in this region, insufficient sophisticated central laboratory testing services, and potential cost effectiveness of POC molecular diagnosis.

Which segment is held the largest share in the point-of-care molecular diagnostics market?

In 2021, the assays and kits segment is estimated to account for the largest market share in the global point-of-care molecular diagnostics market. POC molecular diagnostic assays and kits are specially designed for point of care such as hospital critical care units, physician offices, outpatient clinics, and community health posts. POC molecular diagnostics assays and kits enable the early diagnosis of infectious diseases, cancer, and women’s health and sexual health conditions among others.

The List of Companies - Point-of-Care Molecular Diagnostics Market

  1. bioMérieux SA
  2.  F. Hoffmann-La Roche Ltd.
  3. Danaher Corporation
  4.  Enzo Biochem, Inc.
  5. Abbott
  6. binx health, Inc.
  7. Meridian BioScience, Inc.
  8. Biocartis
  9. Quidel Corporation
  10. Bio-Rad Laboratories, Inc.

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports